ZHONGHENG GROUP(SH:600252)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥640,505,143.11, a decrease of 44.54% compared to the same period last year[6] - Net profit attributable to shareholders was ¥85,822,618.97, down 52.44% year-on-year[6] - The net cash flow from operating activities was -¥55,021,780.87, representing a decline of 633.90% compared to the previous year[6] - Basic earnings per share were ¥0.0249, a decrease of 52.75% from the same period last year[6] - Total operating revenue for Q1 2022 was CNY 640,505,143.11, a decrease of 44.5% compared to CNY 1,154,801,429.41 in Q1 2021[32] - Net profit for Q1 2022 was CNY 57,322,111.10, a decline of 73.7% compared to CNY 217,859,346.06 in Q1 2021[34] - The total comprehensive income attributable to the parent company was CNY 20,872,621.78, a decrease from CNY 39,931,771.82 in the same period last year, reflecting a decline of approximately 47.8%[36] - Basic and diluted earnings per share were both CNY 0.0249, down from CNY 0.0527 in the same quarter last year, reflecting a decline of approximately 52.8%[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,997,417,716.07, an increase of 0.91% from the end of the previous year[8] - The total assets of Guangxi Wuzhou Zhongheng Group reached CNY 11.99 billion, an increase from CNY 11.89 billion in the previous period[26] - The company's total liabilities increased to CNY 3,315,919,320.76 in Q1 2022 from CNY 3,199,922,228.99 in Q1 2021, representing a growth of 3.6%[30] - The total liabilities decreased to CNY 6.06 billion from CNY 6.09 billion, showing a reduction of 0.5%[26] Cash Flow - Cash inflow from operating activities totaled CNY 813,405,013.30, down from CNY 1,165,571,553.59 year-over-year, representing a decrease of about 30.2%[38] - The company reported cash outflows from operating activities of CNY 868,426,794.17, compared to CNY 1,155,265,968.02 in the previous year, marking a reduction of approximately 25%[42] - Investment activities resulted in a net cash flow of CNY -146,738,652.98, a stark contrast to a positive CNY 150,252,474.02 in the same quarter last year[42] - The total cash outflow for investment activities was CNY 171,916,333.95, compared to CNY 111,418,769.41 in Q1 2021, representing an increase of approximately 54.3%[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 147,382[11] - The largest shareholder, Guangxi Investment Group Co., Ltd., held 27.73% of the shares, with 297,794,118 shares pledged[11] - The company reported a total of 13,523,443 shares repurchased, accounting for 0.39% of the total share capital as of March 31, 2022[15] - The company’s major shareholder, Guangxi Investment Group Co., Ltd., holds 963,596,802 shares, representing a significant portion of the total shares[15] - The company has multiple asset management plans from various funds, each holding 25,335,000 shares, indicating strong institutional interest[15] - The company’s total shareholding structure includes significant stakes from various funds, with the largest being Guangxi Investment Group Co., Ltd.[15] - The company has not disclosed any known relationships or concerted actions among its top shareholders[15] - The company’s total number of shares held by the top ten unrestricted shareholders includes significant holdings from various funds and individuals[15] Operational Changes and Developments - The decline in operating revenue was primarily due to the impact of the pandemic, medical insurance policies, and centralized procurement policies affecting sales[10] - The company reported non-recurring gains of ¥11,687,201.74 from government subsidies closely related to its normal business operations[8] - The company’s management has undergone changes, with the resignation of General Manager Jiang Shenzhou on January 16, 2022[16] - The company is actively managing its stock incentive plan, with the first grant completed on February 14, 2022[18] - Laimei Pharmaceutical's injection of methylprednisolone sodium succinate received approval for consistency evaluation in February 2022, enhancing its market position[20] - The total estimated investment for the construction of the Zhongheng Pharmaceutical Intelligent Manufacturing Valley project is approximately CNY 432.37 million, with a planned construction period of 34 months and an investment recovery period of 4.65 years[20] - The partnership agreement for the Xiamen Lisu Investment Partnership was amended, increasing the total scale from CNY 10,000 to CNY 400 million, with the company committing up to CNY 150 million[22] Research and Development - Research and development expenses for Q1 2022 were CNY 45,658,550.65, an increase of 63.7% compared to CNY 27,879,204.27 in Q1 2021[32]